期刊文献+

恶性疟原虫信号肽肽酶-绿色荧光蛋白突变株的建立及其在疟原虫体内的表达分析

Construction of Plasmodium falciparum Signal Peptide Peptidase-GFP Mutant and its Expression Analysis in the Malaria Parasite
下载PDF
导出
摘要 目的构建恶性疟原虫(Plasmodium falciparum)信号肽肽酶(PfSPP)基因转染载体,筛选可在体内表达疟原虫信号肽肽酶-绿色荧光蛋白(PfSPP-GFP)的疟原虫。方法提取Trager-Jensen法培养的恶性疟原虫3D7株基因组DNA,PCR扩增PfSPP C端不含终止密码子的883 bp基因片段,克隆构建重组转染载体pSPPcGT。重组载体经PCR和双酶切鉴定后送测序。电转化法将重组载体转染入恶性疟原虫体内,采用5 nmol/L恶性疟原虫二氢叶酸还原酶抑制剂WR99210筛选转染后,恶性疟原虫经无水乙醇固定、4′,6-二脒基-2-苯基吲哚(DAPI)染色后,荧光显微镜下观察PfSPP-GFP在其体内的表达分布情况。提取筛选后恶性疟原虫全蛋白,Western blotting分析虫体内PfSPP-GFP蛋白的表达情况。结果 PCR扩增获得PfSPP基因C端不含终止密码子的DNA片段,大小为883 bp。构建的重组转染载体pSPPcGT经PCR鉴定、双酶切鉴定和测序鉴定均正确。荧光显微镜观察结果显示,筛选后恶性疟原虫细胞内有绿色荧光蛋白表达,主要位于细胞质中,表明PfSPP-GFP已成功转染至恶性疟原虫并表达。Western blotting分析结果显示,转染的恶性疟原虫可表达含PfSPP-GFP融合蛋白,与预期相对分子质量(Mr)64 000大小一致。结论构建了恶性疟原虫PfSPP-GFP重组转染载体,筛选获得了能在疟原虫体内表达PfSPP-GFP的突变株。 Objective To construct recombinant plasmid pSPPcGT which contains signal peptide peptidase gene of Plasmodium falciparum(PfSPP) and GFP, and transfect into P. falciparum(3D7 strain) to obtain mutant parasites which can express PfSPP-GFP. Methods Plasmodium falciparum(3D7 strain) genomic DNA was extracted from cultured malaria parasites. The C-terminal region of PfSPP, an 883 bp gene fragment was amplified by PCR, and then cloned into pPM2 GT vector to get recombinant vector pSPPcGT. The recombinant vectors were identified by PCR, double restriction enzyme digestion and DNA sequencing. pSPPcGT vector was transfected into malaria parasites. The positive clones were selected by adding inhibitor of Plasmodium falciparum dihydrofolate reductase WR99210 to the culture medium. The pSPP-GFP-transfected parasites were fixed with methanol, stained with DAPI, and observed under immunofluorescence microscope. The PfSPP-GFP expression in P. falciparum was identified by SDS-PAGE and Western blotting. Results The C-terminal region of PfSPP was amplified from P. falciparum(3D7 strain) genomic DNA by PCR with the length of883 bp. The constructed recombinant vectors were identified by PCR screening, double restriction enzyme digestion and DNA sequencing. The pSPPcGT vector was transfected into P. falciparum and the positive clones were selected by WR99210. GFP fluorescence was observed in transfected parasites by immunofluorescence microscopy, and mainly located in the cytoplasm. The PfSPP-GFP expression in malaria parasites was confirmed by Western blotting with a relative molecular mass of Mr64 000. Conclusion Recombinant vector PfSPP-GFP is constructed and transfected into P. falciparum to obtain P. falciparum mutant clone which can express PfSPP-GFP.
出处 《中国寄生虫学与寄生虫病杂志》 CAS CSCD 北大核心 2014年第4期253-257,共5页 Chinese Journal of Parasitology and Parasitic Diseases
基金 广东省自然科学基金(No.S2012010008504) 高等学校学科创新引智计划(No.B12003) 中山大学人才项目(No.50000-3182305)~~
关键词 恶性疟原虫 信号肽肽酶 绿色荧光蛋白 转染 Plasmodium falciparum Signal peptide peptidase Green fluorescent protein Transfection
  • 相关文献

参考文献18

  • 1Plowe CV. Malaria: Resistance nailed [J]. Nature, 2014, 505(7481): 30-31.
  • 2Moorthy VS, Newman RD, Okwo-Bele JM. Malaria vaccine tech- nology roadmap[J]. Lancet, 2013, 382(9906): 1700-1701.
  • 3曹俊(综述,高琪(审校).疟疾疫苗现场试验研究进展[J].中国寄生虫学与寄生虫病杂志,2008,26(6):472-475. 被引量:5
  • 4张冬梅,潘卫庆.我国疟疾疫苗研究进展及前景[J].中国寄生虫学与寄生虫病杂志,2009,27(5):390-393. 被引量:12
  • 5Mutabingwa TK. Artemisinin-based combination therapies (ACTs): best hope for malaria treatment but inaccessible to the needy[J]. Acta Trop, 2005, 95(3): 305-315.
  • 6Rogers WO, Sem R, Tero T, et ol. Failure of artesunate-meflo- quine combination therapy for uncomplicated Plasmodium falci- parum malaria in southern Cambodia [J]. Malar J, 2009, 8: 10.
  • 7Na-Bangchang K, Ruengwecrayut R, Mahamad P, et al. Declin- ing in efficacy of a three-day combination regimen of mefloquine- artesunate in a multi-drug resistance area along the Thai-Myan- mar border[J]. Malar J, 2010, 9: 273.
  • 8Na-Bangchang K, Muhamad P, Ruaengweerayut R, et al. Iden- tification of resistance of Plasmodium falciparum to artesunate- mefloquine combination in an area along the Thai-Myanmar bor- der: integration of clinieo-parasitological response, systemic drug exposure, and in vitro parasite sensitivity [J]. Malar J, 2013, 12: 263.
  • 9Weihofen A, Binns K, Lemberg MK, et al. Identification of signal peptide peptidase, a presenilin-type aspartic protease [J]. Science, 2002, 296(5576): 2215-2218.
  • 10Casso DJ, Tanda S, Biehs B, et al. Drosophila signal peptide peptidase is an essential protease for larval development [J]. Genetics, 2005, 170(1): 139-148.

二级参考文献54

  • 1李淑梅,李珣,缪军,刘忠湘,薛采芳.以恶性疟原虫MSP1和AMA1疫苗组合免疫小鼠诱导保护性免疫[J].中国人兽共患病学报,2006,22(10):936-940. 被引量:3
  • 2Snow RW, Guerra CA, Noor AM, et al. The global distribution of clinical episodes of Plasmodium falciparum malaria[J]. Nature, 2005, 434(7030): 214-217.
  • 3Guerra CA, Snow RW, Hay SI. Mapping the global extent of malaria in 2005[J]. Trends Parasitol, 2006, 22(8): 353-358.
  • 4WHO Expert Committee on Malaria. World Health Organ Tech Rep Ser, 2000, 892(i-v): 1-74.
  • 5Cohen S, Butcher GA. Properties of protective malarial antibody [J]. Nature, 1970, 225(5234): 732-734.
  • 6Hoffman SL, Goh LM, Luke TC, et al. Protection of humans against malaria by immunization with radiation-attenuated Plasmodiumfalciparum sporozoites[J]. J Infect Dis, 2002, 185(8): 1155- 1164.
  • 7Waters A. Malaria: new vaccines for old[J]. Cell, 2006, 124(4): 689-693.
  • 8Ripley Ballou W. Obstacles to the development of a safe and effective attenuated pre-erythrocytic stage malaria vaccine[J]. Microbes Infect, 2007, 9(6): 761-766.
  • 9Alonso PL, Sacarlal J, Aponte JJ, et al. Efficacy of the RTS,S/ AS02A vaccine against Plasmodium falclparum infection and disease in young African children: randomised controlled trial[J]. Lancet, 2004, 564(9445): 1411-1420.
  • 10Alonso PL, Sacarlal J, Aponte JJ, et al. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a raudomised controlled trial[J]. Lancet, 2005, 366 (9502) : 2012-2018.

共引文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部